Literature DB >> 27695682

The experience of bedaquiline implementation at a decentralised clinic in South Africa.

R Cariem1, V Cox2, V de Azevedo3, J Hughes2, E Mohr2, L Triviño Durán2, N Ndjeka4, J Furin5.   

Abstract

Multidrug-resistant tuberculosis (MDR-TB) is a serious public health problem, but the new drugs bedaquiline (BDQ) and delamanid offer hope to improve outcomes and minimise toxicity. In Khayelitsha, South Africa, patients are routinely started on BDQ in the out-patient setting. This report from the field describes BDQ use in the out-patient setting at the Nolungile Clinic. The clinic staff overall report a positive experience using the drug. Challenges have been based largely on the logistics of drug supply and delivery. BDQ can be started successfully in the out-patient setting, and can be a positive experience for both patients and providers. La tuberculose multirésistante (TB-MDR) est un problème de santé publique grave, mais les nouveaux médicaments que sont la bédaquiline (BDQ) et le délamanide apportent un espoir d'améliorer les résultats tout en réduisant la toxicité. A Khayelitsha, Afrique du Sud, les patients démarrent leur traitement par BDQ en consultation externe en routine. Ce rapport du terrain décrit l'utilisation de la BDQ à la consultation externe du dispensaire Nolungile. Dans l'ensemble, le personnel du centre de santé exprime une expérience positive du médicament. Les défis ont surtout été liés à la logistique de l'approvisionnement et de la distribution du médicament. La BDQ peut être mise en route avec succès dans le cadre d'une consultation externe et peut constituer une expérience positive pour les patients et les prestataires de soins. La tuberculosis multirresistente (TB-MDR) representa un grave problema de salud pública, pero la utilización de nuevos medicamentos como la bedaquilina (BDQ) y el delamanid ofrece perspectivas de mejores desenlaces terapéuticos y disminución de la toxicidad asociada. En Khayelitsha, Suráfrica, se inicia de manera sistemática el tratamiento ambulatorio con BDQ. En el presente informe del terreno, se describe la utilización de BDQ en tratamiento antituberculoso ambulatorio en el centro de atención Nolungile. En general, los miembros del personal del centro refirieron una experiencia positiva con la administración del medicamento. Las dificultades surgieron en gran parte con respecto a aspectos logísticos del suministro y la administración del medicamento. Es posible iniciar un tratamiento eficaz con BDQ en condiciones ambulatorias, y represente una experiencia positiva para los pacientes y los profesionales de salud.

Entities:  

Keywords:  BDQ; Khayelitsha; MDR-TB; Nolungile; decentralised

Year:  2016        PMID: 27695682      PMCID: PMC5034785          DOI: 10.5588/pha.16.0037

Source DB:  PubMed          Journal:  Public Health Action        ISSN: 2220-8372


  5 in total

1.  Cohort Profile: The Khayelitsha antiretroviral programme, Cape Town, South Africa.

Authors:  Kathryn Stinson; Eric Goemaere; David Coetzee; Gilles van Cutsem; Katherine Hilderbrand; Meg Osler; Claudine Hennessey; Lynne Wilkinson; Gabriela Patten; Carol Cragg; Shaheed Mathee; Vivian Cox; Andrew Boulle
Journal:  Int J Epidemiol       Date:  2017-04-01       Impact factor: 7.196

2.  Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis.

Authors:  N Ndjeka; F Conradie; K Schnippel; J Hughes; N Bantubani; H Ferreira; G Maartens; D Mametja; G Meintjes; X Padanilam; E Variava; A Pym; Y Pillay
Journal:  Int J Tuberc Lung Dis       Date:  2015-08       Impact factor: 2.373

3.  Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence.

Authors:  Jason E Farley; Malathi Ram; William Pan; Stacie Waldman; Gail H Cassell; Richard E Chaisson; Karin Weyer; Joey Lancaster; Martie Van der Walt
Journal:  PLoS One       Date:  2011-07-22       Impact factor: 3.240

4.  Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients.

Authors:  Shama D Ahuja; David Ashkin; Monika Avendano; Rita Banerjee; Melissa Bauer; Jamie N Bayona; Mercedes C Becerra; Andrea Benedetti; Marcos Burgos; Rosella Centis; Eward D Chan; Chen-Yuan Chiang; Helen Cox; Lia D'Ambrosio; Kathy DeRiemer; Nguyen Huy Dung; Donald Enarson; Dennis Falzon; Katherine Flanagan; Jennifer Flood; Maria L Garcia-Garcia; Neel Gandhi; Reuben M Granich; Maria G Hollm-Delgado; Timothy H Holtz; Michael D Iseman; Leah G Jarlsberg; Salmaan Keshavjee; Hye-Ryoun Kim; Won-Jung Koh; Joey Lancaster; Christophe Lange; Wiel C M de Lange; Vaira Leimane; Chi Chiu Leung; Jiehui Li; Dick Menzies; Giovanni B Migliori; Sergey P Mishustin; Carole D Mitnick; Masa Narita; Philly O'Riordan; Madhukar Pai; Domingo Palmero; Seung-kyu Park; Geoffrey Pasvol; Jose Peña; Carlos Pérez-Guzmán; Maria I D Quelapio; Alfredo Ponce-de-Leon; Vija Riekstina; Jerome Robert; Sarah Royce; H Simon Schaaf; Kwonjune J Seung; Lena Shah; Tae Sun Shim; Sonya S Shin; Yuji Shiraishi; José Sifuentes-Osornio; Giovanni Sotgiu; Matthew J Strand; Payam Tabarsi; Thelma E Tupasi; Robert van Altena; Martie Van der Walt; Tjip S Van der Werf; Mario H Vargas; Pirett Viiklepp; Janice Westenhouse; Wing Wai Yew; Jae-Joon Yim
Journal:  PLoS Med       Date:  2012-08-28       Impact factor: 11.069

5.  Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis.

Authors:  Jennifer Furin; Grania Brigden; Erica Lessem; Michael Rich; Laura Vaughan; Sharonann Lynch
Journal:  Emerg Infect Dis       Date:  2016-03       Impact factor: 6.883

  5 in total
  5 in total

Review 1.  Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective.

Authors:  Emily A Kendall; Ted Cohen; Carole D Mitnick; David W Dowdy
Journal:  Int J Infect Dis       Date:  2016-12-19       Impact factor: 3.623

Review 2.  Effectiveness of the Novel Anti-TB Bedaquiline against Drug-Resistant TB in Africa: A Systematic Review of the Literature.

Authors:  Afsatou Ndama Traoré; Mpumelelo Casper Rikhotso; Ntshuxeko Thelma Banda; Maphepele Sara Mashilo; Jean Pierre Kabue Ngandu; Vuyo Mavumengwana; Andre G Loxton; Craig Kinnear; Natasha Potgieter; Scott Heysell; Rob Warren
Journal:  Pathogens       Date:  2022-06-01

3.  Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children.

Authors:  Elin M Svensson; Jeannine du Bois; Rene Kitshoff; Veronique R de Jager; Lubbe Wiesner; Jennifer Norman; Sharon Nachman; Betsy Smith; Andreas H Diacon; Anneke C Hesseling; Anthony J Garcia-Prats
Journal:  Br J Clin Pharmacol       Date:  2018-06-27       Impact factor: 4.335

4.  QT Interval Prolongation in People Treated With Bedaquiline for Drug-Resistant Tuberculosis Under Programmatic Conditions: A Retrospective Cohort Study.

Authors:  Sharon Isralls; Kathy Baisley; Eric Ngam; Alison D Grant; James Millard
Journal:  Open Forum Infect Dis       Date:  2021-08-01       Impact factor: 3.835

5.  Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa.

Authors:  Erika Mohr-Holland; Anja Reuter; Jennifer Furin; Anthony Garcia-Prats; Virginia De Azevedo; Vanessa Mudaly; Yulene Kock; Laura Trivino-Duran; Petros Isaakidis; Jennifer Hughes
Journal:  EClinicalMedicine       Date:  2020-03-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.